Assembly Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 20.13 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 409.86M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Details
| Name | Assembly Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 73 |
| Founded | 2005 |
| Ipo Date | 2010-12-17 |
| Ceo | Jason Okazaki |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US0453962070 |
| Cusip | 045396207 |
| Cik | 0001426800 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Jason A. Okazaki J.D. | Chief Executive Officer, President and Director |
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer |
| Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer |
| Jeanette M. Bjorkquist | Principal Financial Officer, Executive Director of Accounting and Treasury |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs and Alliance Management |
| Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer |
| Katie Kitrinos | Senior Vice President of Preclinical Research and Development |
| Thomas E. Rollins | Executive Officer |
| Amy Figueroa C.F.A. | Investor Relations Consultant |
Contact
| Address | Two Tower Place, 7th Floor, South San Francisco, California 94080, United States |
| Phone | 833 509 4583 |
| Website | https://www.assemblybio.com |